news
bit.bio raises $103 million in first close of Series B financing
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
List view / Grid view
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.